Daily Magnesium improved all aspects of metabolic profile – RCT

Created October 2014

Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.

Arch Med Res. 2014 Jul;45(5):388-93. doi: 10.1016/j.arcmed.2014.05.003. Epub 2014 May 13.

Rodríguez-Moran M1, Guerrero-Romero F2 [email protected]

Author information

1 Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.

2 Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.

Magnesium Chloride containing 386 mg MgBoth obese and normal weight individuals had similar benefit| | | || --- | --- | --- || | Mg | Control || Systolic blood pressure | -2 mm | * 4 mm || Diastolic blood pressure | -4 mm | * 8 mm || HOMA-IR index | -47%. | -5% || Fasting glucose | -12% | -2% mg/dL || Triglyceride levels | -47% | 10% | 1. See also Vitamin D Life* Search Vitamin D Life for HOMA-IR 86 items as of Oct 2014* 4000 IU RCT reduces type 2 diabetes HOMA by 24% and CRP by 64% April 2010* Overview Magnesium and vitamin D* Overview Metabolic Syndrome and vitamin D* Overview Diabetes and vitamin D contains the following summary{include}The TOP Metabolic Syndrom articles are here: {category}

BACKGROUND AND AIMS:

We undertook this study to determine the efficacy of oral magnesium supplementation in the improvement of the metabolic profile and blood pressure in metabolically obese, normal-weight (MONW) individuals.

METHODS:

A total of 47 MONW individuals with hypomagnesemia were enrolled in clinical a randomized double-blind placebo-controlled trial. Individuals in the intervention group received 30 mL of MgCl2 5% solution (equivalent to 382 mg of magnesium) and individuals in the control group 30 mL of placebo solution, once daily during 4 months. In the absence of obesity or overweight, the presence of fasting glucose levels ≥100 mg/dL, HOMA-IR index ≥3, triglyceride levels ≥150 mg/dL and/or systolic and diastolic blood pressure ≥140 and 90 mmHg defined the presence of the MONW phenotype. Hypomagnesemia was defined by serum magnesium concentration ≤1.8 mg/dL.

RESULTS:

At basal conditions there were no significant differences between groups. At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.

CONCLUSIONS:

Oral magnesium supplementation improves the metabolic profile and blood pressure of MONW individuals.

PMID: 24830937

Tags: Diabetes Magnesium Metabolic Syndrome